Loading...

Brilliant Violet 605™ anti-mouse Ly-6A/E (Sca-1) Antibody

Pricing & Availability
Clone
D7 (See other available formats)
Regulatory Status
RUO
Other Names
Sca-1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
D7_BV605_LY-6AE_Antibody_FC_071013
C57BL/6 mouse splenocytes were stained with Ly-6A/E (clone D7) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).
  • D7_BV605_LY-6AE_Antibody_FC_071013
    C57BL/6 mouse splenocytes were stained with Ly-6A/E (clone D7) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).
Compare all formats See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
108133 125 µL £151
Check Availability


Need larger quantities of this item?
Request Bulk Quote
108134 50 µg £180
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Ly-6A/E, also known as Sca-1, is an 18 kD member of the Ly-6 multigene family. Ly6A/E is a glycosylphosphatidylinositol (GPI)-linked protein expressed on hematopoietic stem cells. In mice expressing the Ly-6.2 haplotype (e.g., AKR, C57BL, C57BR, DBA/2, SJL, SWR, and 129), Ly-6A/E is also expressed on peripheral B lymphocytes and thymic and peripheral T lymphocytes. Strains expressing the Ly-6.1 haplotype (e.g., BALB/c, CBA, C3H/He, DBA/1, and NZB) have low Ly-6A/E expression on resting peripheral lymphocytes. The expression of Ly-6A/E on lymphocytes is upregulated upon activation from both Ly6.1 and Ly6.2 haplotype mice. Ly-6A/E is thought to be involved in the regulation of both T and B cell responses.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-dependent mouse T-cell line (CTL-L)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The D7 antibody has been reported to induce T cell activation and inhibit TCR-induced IL-2 production. Additional reported applications (for the relevant formats) include: Western blotting1,2, immunoprecipitation1, in vitro lymphocyte activation3-6, induction of redirected lysis7, induction of T cell inhibitory signalling8, immunofluorescence9, and immunohistochemical staining of acetone-fixed frozen sections13 and Bouin-fixed, paraffin-embedded samples9.

The two Sca-1 recognizing clones D7 and E13-161.7 have been shown to bind distinct epitopes due to the inability of D7 to block the binding of E13-161.7.14 

Application References

(PubMed link indicates BioLegend citation)
  1. Ortega G, et al. 1986. J. Immunol. 137:3240. (WB, IP)
  2. Palfree RGE, et al. 1986. Immunogenetics 23:197. (WB)
  3. Codias EK, et al. 1990. J. Immunol. 144:2197.
  4. Malek TR, et al. 1986. J. Exp. Med. 164:709.
  5. Codias EK, et al. 1990. J. Immunol. 145:1407.
  6. Ivanov V, et al. 1994. J. Immunol. 153:2394.
  7. Karlhofer FM, et al. 1991. J. Immunol. 146:3662.
  8. Fleming T, et al. 1994. J. Immunol. 153:1955.
  9. van Bragt MPA, et al. 2005. Biol. Reprod. 73:634. (IF, IHC)
  10. Umland O, et al. 2007. J. Immunol. 178:4147.
  11. Cridland SO, et al. 2009. Blood Cell. Mol. Dis. 45:149. (FC) PubMed
  12. Pronk CJ, et al. 2011. J. Exp Med. PubMed
  13. English A, et al. 2000. J. Immunol. 165:3763. (IHC)
  14. Bamezai A and Rock KL. 1995. Proc. Natl. Acad. Sci. USA 92:4294.
  15. Wiesner DL, et al. 2015. PLoS Pathog. 11:1004701. PubMed
Product Citations
  1. Kenigsbuch M, et al. 2022. Nat Neurosci. 25:876. PubMed
  2. Edwards SC, et al. 2023. J Exp Med. 220: . PubMed
  3. Zhang LJ, et al. 2019. Immunity. 50:121. PubMed
  4. Salzer MC et al. 2018. Cell. 175(6):1575-1590 . PubMed
  5. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
  6. Schloss MJ, et al. 2022. Nat Immunol. 23:605. PubMed
  7. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  8. Hu X, et al. 2016. Nat Commun. 7:13095. PubMed
  9. Boothby IC, et al. 2021. Nature. 599:667. PubMed
  10. Di Genua C, et al. 2020. Cancer Cell. 37(5):690-704.e8.. PubMed
  11. Kumar B, et al. 2020. Haematologica. Online ahead of print:. PubMed
  12. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  13. Booth CAG, et al. 2018. Cancer Cell. 33:274. PubMed
  14. Comoglio F, et al. 2018. Genome Res. 10.1101/gr.227272.117. PubMed
  15. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  16. Leavitt T, et al. 2020. Cell Rep. 33:108356. PubMed
  17. Kwok T, et al. 2022. Front Aging. 3:838943. PubMed
  18. Jaitin DA et al. 2016. Cell. 167(7):1883-1896 . PubMed
  19. Dokoshi T, et al. 2020. Cell Rep. 30:61. PubMed
  20. Huang S, et al. 2021. Cell Stem Cell. . PubMed
  21. Dhayade S, et al. 2020. Nutrients. 12:. PubMed
  22. Mathur AN, et al. 2019. Immunity. 50:655. PubMed
  23. Braza MS et al. 2018. Immunity. 49(5):819-828 . PubMed
  24. Borrelli MR, et al. 2020. Stem Cells Transl Med. 1.347916667. PubMed
RRID
AB_2562275 (BioLegend Cat. No. 108133)
AB_2562275 (BioLegend Cat. No. 108134)

Antigen Details

Structure
Ly-6 multigene family, 18 kD
Distribution

Hematopoietic stem cells, activated T cells and B cells, subset of resting B cells and T cells

Function
Regulates B and T cell responses
Cell Type
B cells, Hematopoietic stem and progenitors, Mesenchymal Stem Cells, T cells
Biology Area
Immunology, Stem Cells
Antigen References

1. Rock KL, et al. 1989. Immunol. Rev. 111:195.
2. Morrison SJ, et al. 1994. Immunity 1:661.
3. Spangrude GJ, et al. 1988. J. Immunol. 141:3697.
4. Malek T, et al. 1986. J. Exp. Med. 164:709.

Gene ID
110454 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
Ly-6A/E
Specificity Alt (DOES NOT SHOW ON TDS):
Ly-6A/E
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about Ly-6A/E on UniProt.org
Go To Top Version: 2    Revision Date: 07/17/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account